Cost-effectiveness of a hypertension control intervention in three community health centers in China

Journal of Primary Care and Community Health

Volumn 4, Issue 3, 2013, Pages 195-201

  Bai, Yamin ^a   Zhao, Yanfang ^a   Wang, Guijing ^b   Wang, Huicheng ^a   Liu, Kejun ^c   Zhao, Wenhua ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c China National Development Research Center   (China)

Author keywords

Blood pressure; China; Community; Economic evaluation; Intervention

Indexed keywords

AGED; ARTICLE; BLOOD PRESSURE; CHINA; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; ECONOMICS; FEMALE; HEALTH CENTER; HUMAN; HYPERTENSION; INTERVENTION; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

BLOOD PRESSURE; CHINA; COMMUNITY; ECONOMIC EVALUATION; INTERVENTION;

AGED; CHINA; COMMUNITY HEALTH CENTERS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84905637451     PISSN: 21501319     EISSN: 21501327     Source Type: Journal    
DOI: 10.1177/2150131912470459     Document Type: Article

References (28)

1. Mohan S, Campbell NR. Hypertension management in Canada: good news, but important challenges remain. CMAJ. 2008;178: 1458-1460.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease. Lancet. 1997;349:1436-1442.
3. Wolf-Maier K, Coper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363-2369.
4. Gu D, Reynolds K, Wu X, et al. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension. 2002;40:920-927.
5. Meng XJ, Dong GH, Wang D, et al. Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities in China: the CHPSNE study. J Hypertens. 2011;29:1303-1310.
6. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124-1134.
7. Yang G. Chronic diseases in China: challenges and countermeasures. Paper presented at: 2007 Shanghai International Symposium on Public Health; 2007:8-9.
8. Zhang W. Chronic disease prevention and control needs to be strengthened. J People's Politi Consult Conf. 2010;3:C02.
9. Zhai Y, Hu JP, Kong LZ, Zhao WH, Chen CM. Economic burden of coronary heart disease and stroke attributable to hypertension in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2006;27:744-747.
10. Datta SK, Oddone EZ, Olsen MK, et al. Economic analysis of a tailored behavioral intervention to improve blood pressure control for primary care patients. Am Heart J. 2010;160:257-263.
11. Chapman RH, Kowal SL, Cherry SB, Ferrufino CP, Roberts CS, Chen L. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications. Value Health. 2010;13: 685-694.
12. Ly D, Alex FZ, Christopher H. Cost-effectiveness analysis of a hypertension management program in patients with type 2 diabetes. J Clin Hypertens. 2009;11:116-124.
13. Yosefy C, Ginsberg G, Viskoper R, Dicker D, Gavish D. Costutility analysis of a national project to reduce hypertension in Israel. Cost Eff Resour Alloc. 2007;5:16-26.
14. Gandjour A, Stock S. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy. 2007;83:257-267.
15. Deng BH, Liu HW, Pan PC, Mau LW, Chiu HC. Costeffectiveness of elderly health examination program: the example of hypertension screening. Kaohsiung J Med Sci. 2007;23:17-24.
16. Brunenberg DE, Wetzels GE, Nelemans PJ, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics. 2007;25:239-251.
17. Booth N, Jula A, Aronen P, et al. Cost-effectiveness analysis of guidelines for antihypertensive care in Finland. BMC Health Serv Res. 2007;7:172-185.
18. Rodriguez-Roca GC, Alonso-Moreno FJ, Garcia-Jimenez A, et al. Cost-effectiveness of ambulatory blood pressure monitoring in the follow-up of hypertension. Blood Press. 2006;15:27-36.
19. Cheng X, Sheng F, Chen Y, et al. The cost accounting of urban community health service (I). Chin Health Econ. 2004;23:19.
20. Tan-Torres Edejer T, Baltussen R, Adam T, eds. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva, Switzerland: World Health Organization; 2003. http://www.who.int/choice/publications/p_2003_generalised_ cea.pdf. Accessed August 2, 2011.
21. Moser M, Franklin SS, Handler J. The nonpharmacologic treatment of hypertension: how effective is it? An update. J Clin Hypertens. 2007;9:209-216.
22. Dickinson HO, Mason JM, Nicholson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24: 215-233.
23. Applegate WB, Miller ST, Elam JT, et al. Nonpharmacologic intervention to reduce blood pressure in older patients with mild hypertension. Arch Intern Med. 1992;152:1162-1166.
24. Unal B, Critchley JA, Capewell S. Small changes in the United Kingdom cardiovascular risk factors could halve coronary heart disease mortality. J Clin Epidemiol. 2005;58:733-740.
25. Li H, Meng Q, Sun X, Salter A, Briggs NE, Hiller JE. Prevalence, awareness, treatment, and control of hypertension in rural China: results from Shandong province. J Hypertens. 2010;28:432-438.
26. Sun Z, Zheng L, Detrano R, et al. Incidence and predictors of hypertension among rural Chinese adults: results from Liaoning province. Ann Fam Med. 2010;8:19-24.
27. Cai L, Shu Z, Dong J, Zhao K. The economic burden of hypertension in rural south-west China. Trop Med Int Health. 2012;17:1544-1551. doi:10.1111/j.1365-3156.2012.03087.x.
28. Yu B, Zhang X, Wang G. Effectiveness of full coverage for hypertension drugs in rural communities in Shandong, China. Am J Manag Care. In press.